Robbins Geller Files Class Action Against RxSight: What Investors Need to Know

Class Action Lawsuit Filed Against RxSight, Inc.

In a significant step for investors, Robbins Geller Rudman & Dowd LLP has initiated a class action lawsuit targeting RxSight, Inc. (NASDAQ: RXST), a company specializing in medical technology designed for cataract treatment. The lawsuit, filed in the Central District of California under the case name Gémesi v. RxSight, Inc., seeks to represent shareholders who purchased RxSight's common stock between May 7, 2024, and July 8, 2025. This period is identified as the 'Class Period.'

Allegations Against RxSight

The class action lawsuit centers around accusations that RxSight and certain executives have breached the Securities Exchange Act of 1934. The suit claims that throughout the Class Period, the company misrepresented key operational metrics. RxSight allegedly promoted misleading information concerning the uptake of their Light Adjustable Lens (LAL) and their light delivery devices (LDD). The company purported that sales were rising significantly; however, the reality differed markedly.

The lawsuit highlights several key allegations:
1. Misleading Performance Metrics: RxSight claimed that utilization metrics across their installed base were improving and that new customer cohorts were adopting their products at comparable rates to prior cohorts. In truth, these new cohorts were reportedly slower to adopt and required more assistance.
2. Underperforming Field Support: The suit also alleges that RxSight’s support teams were inadequately structured and failed to provide the necessary backing to practices needed to boost growth in LAL procedures.
3. Revenue Declines: The company faced a severe downturn, as evidenced when they announced on April 2, 2025, that LAL sales had sequentially dropped, resulting in a revenue forecast reduction of approximately $24 million. This caused RxSight's stock price to plummet by about 38% on the announcement.
4. Continued Sales Drop: The lawsuit further contends that by July 8, 2025, a stark decline of 45% in LDD sales was revealed, alongside another consecutive quarterly sales drop for LAL, highlighting deeper issues within the company's operational strategy.

These allegations depict a troubling narrative that caused significant financial strain on shareholders, leading up to this lawsuit aiming to seek justice for the investors affected.

The Role of a Lead Plaintiff

Investors who have incurred substantial losses are encouraged to consider stepping forward as lead plaintiffs in the class action. According to the Private Securities Litigation Reform Act of 1995, any individual who acquired shares during the Class Period may seek this role. The lead plaintiff is typically the one who has the most substantial financial interest in the case and is representative of the group being addressed.

If you believe you meet the criteria and wish to take on this role, Robbins Geller provides a resource for potential lead plaintiffs who can express their interest and submit necessary information through their website.

The Importance of Legal Representation

Robbins Geller Rudman & Dowd LLP brings a wealth of experience in securities class action litigation. Over recent years, they have secured millions in recoveries for investors, further establishing the firm as a leading force against financial fraud. For example, they achieved notable recoveries amounting to over $2.5 billion for investors in 2024 alone. The firm’s track record in this sphere underscores the importance of having experienced legal representation when pursuing restitution in complex financial grievances.

Investors seeking to engage with this class action or obtain further insights can reach out to attorneys J.C. Sanchez or Jennifer N. Caringal at Robbins Geller via phone or their professional email.

Conclusion

The unfolding class action against RxSight represents a significant opportunity for shareholders who have suffered losses to potentially recoup damages experienced. As investigations continue regarding the company’s business practices, transparency and accountability remain paramount for the affected investors. Those interested in participating should act quickly, as the deadline for submitting lead plaintiff motions is September 22, 2025. With the potential for substantial recovery, this case is one to watch closely in the coming months.